Parkinson's disease (PD) is the second most common neurodegenerative disorder after Alzheimer's disease, affecting approximately 6 million people worldwide [1]. The disease is characterized by the progressive degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to the cardinal motor symptoms of tremor, bradykinesia, rigidity, and postural instability [2]. Additionally, non-motor symptoms including autonomic dysfunction, sleep disorders, cognitive impairment, and psychiatric manifestations significantly impact patient quality of life [3]. The disease is closely associated with alpha-synuclein aggregation, which forms Lewy bodies in affected neurons, and involves pathways including mitochondrial dysfunction, oxidative stress, and neuroinflammation.
The treatment of Parkinson's disease has evolved dramatically since the introduction of levodopa in the 1960s [4]. Contemporary management focuses on symptomatic control of motor and non-motor symptoms, minimizing motor complications, and ultimately developing disease-modifying therapies that can slow or halt neurodegeneration [5]. This comprehensive review examines current treatment approaches, including pharmacological therapies, surgical interventions, lifestyle modifications, and emerging disease-modifying strategies.
Levodopa (L-3,4-dihydroxyphenylalanine) remains the most effective symptomatic treatment for Parkinson's disease and is considered the gold standard for motor symptom management [6]. As the metabolic precursor of dopamine, levodopa crosses the blood-brain barrier and is decarboxylated to dopamine in the central nervous system [7]. The degeneration of dopaminergic neurons in the substantia nigra leads to the loss of dopaminergic projections to the striatum, disrupting basal ganglia circuitry.
Formulations:
Dosing: Typically initiated at 25/100 mg (carbidopa/levodopa) three times daily and titrated based on response [12]. Maintenance doses usually range from 300-1000 mg of levodopa daily in divided doses [13].
Adverse effects: Nausea, vomiting, hypotension, hallucinations, and motor fluctuations (wear-off, on-off phenomena) [14]. Long-term use is associated with dyskinesias, particularly with high doses and long disease duration [15].
Dopamine agonists directly stimulate dopamine receptors, providing symptomatic relief without the need for dopamine conversion [16]. They are commonly used as first-line therapy in younger patients or as adjuncts to levodopa in advanced disease [17]. These agents act on D2 dopamine receptors in the basal ganglia to restore dopaminergic signaling that is lost due to degeneration of dopaminergic neurons in the substantia nigra.
Oral dopamine agonists:
Adverse effects: Nausea, vomiting, somnolence, impulse control disorders (pathological gambling, shopping, eating), hallucinations, and peripheral edema [22].
MAO-B inhibitors block the enzymatic breakdown of dopamine in the brain, extending the duration of levodopa effect and providing modest symptomatic benefit as monotherapy in early disease [23].
Available agents:
Adverse effects: Headache, nausea, insomnia, confusion, and potential for tyramine interaction (minimal with recommended doses) [27]. Selegiline at high doses may cause hypertension when combined with tyramine-rich foods [28].
Catechol-O-methyltransferase (COMT) inhibitors block the peripheral breakdown of levodopa, increasing its plasma half-life and CNS availability [29].
Agents:
Adverse effects: Dyskinesia (due to increased levodopa availability), nausea, diarrhea, and urine discoloration (entacapone, opicapone) [33]. Tolcapone requires regular liver function monitoring due to rare hepatotoxicity [34].
Anticholinergic agents are primarily used for tremor-predominant PD in younger patients with preserved cognitive function [35].
Agents:
Adverse effects: Cognitive impairment, urinary retention, constipation, dry mouth, and blurred vision [38]. Use is contraindicated in elderly patients due to anticholinergic delirium risk [39].
Originally developed as an antiviral agent, amantadine provides modest antiparkinsonian effects and is uniquely effective in reducing levodopa-induced dyskinesias [40].
Dosing: 100 mg once or twice daily, titrating to 100-400 mg/day [41]
Adverse effects: Livedo reticularis, ankle edema, confusion, hallucinations, and insomnia [42]
Motor fluctuations ("wear-off" and "on-off" phenomena) develop in approximately 50% of patients after 5 years of levodopa treatment [43]. These complications arise from the progressive loss of dopaminergic neurons and the resulting dysregulation of basal ganglia circuitry, particularly involving the direct and indirect pathways that control movement. Management strategies include:
Levodopa-induced dyskinesias (LIDs) affect up to 40% of patients after 5-10 years of treatment [50]. Management approaches include:
Sleep disturbances occur in up to 90% of PD patients and include [56]:
REM Sleep Behavior Disorder (RBD):
Excessive Daytime Sleepiness (EDS):
Insomnia:
Depression:
Psychosis:
Impulse Control Disorders:
Orthostatic hypotension:
Constipation:
Urinary dysfunction:
PD dementia (PDD) affects approximately 30-40% of patients with long disease duration [80]:
Other agents:
Deep brain stimulation (DBS) is the most effective surgical treatment for advanced Parkinson's disease, significantly improving motor symptoms and reducing medication requirements [84]. DBS modulates abnormal basal ganglia output by delivering electrical impulses to specific brain nuclei, effectively bypassing the dysfunction caused by degeneration of dopaminergic neurons.
Targets [85]:
Eligibility criteria [86]:
Outcomes [87]:
Companies and devices [88]:
Intermittent injections: For rescue of "off" episodes, 2-6 mg subcutaneous [92]
Continuous infusion: For advanced disease with motor fluctuations, 1-8 mg/hour subcutaneous [93]
| Agent | Mechanism | Phase | Sponsor |
|---|---|---|---|
| Prasinezumab | Anti-α-synuclein antibody | Phase 2 | Roche |
| BIIB122 (DNL151) | LRRK2 inhibitor | Phase 2b | Biogen/Denali |
| ACI-7104 | α-synuclein vaccine | Phase 1 | AC Immune |
| Venglustat | GCase modulator | Phase 2 | Sanofi |
| Inotrelimab | Anti-CD40 ligand | Phase 2 | Prothelia |
| AAV2-GAD | Gene therapy | Phase 2 | Meirium |
Alpha-synuclein aggregation is a central pathogenic mechanism in Parkinson's disease, making it an attractive therapeutic target [94]. The aggregation of alpha-synuclein protein into Lewy bodies is a hallmark of PD pathology and drives neurodegeneration through mechanisms including mitochondrial dysfunction, oxidative stress, and neuroinflammation.
LRRK2 (leucine-rich repeat kinase 2) mutations are the most common genetic cause of Parkinson's disease, making LRRK2 inhibitors promising disease-modifying agents [98]. The LRRK2 gene encodes a large kinase protein that is implicated in autophagy, lysosomal function, and neuronal survival.
Glucocerebrosidase (GBA) mutations are the most significant genetic risk factor for Parkinson's disease [101]. The GBA gene encodes glucocerebrosidase, a lysosomal enzyme whose dysfunction leads to alpha-synuclein aggregation through impaired autophagy and lysosomal pathways.
Exercise is increasingly recognized as a disease-modifying intervention in PD [104]:
Neuroprotective mechanisms [110]:
Dietary considerations [111]:
Weight management: Both weight loss and obesity may be problematic [112]
Lee Silverman Voice Treatment (LSVT) LOUD [113]:
Swallowing assessment and management [114]:
Interventions [115]:
Biomarker development [122]:
Precision medicine approaches [123]:
First-line options [124]:
Management [125]:
Management [126]:
The treatment of Parkinson's disease has advanced considerably, offering patients multiple therapeutic options to manage motor and non-motor symptoms effectively. While levodopa remains the cornerstone of treatment, the availability of dopamine agonists, MAO-B inhibitors, COMT inhibitors, and device-based therapies provides flexibility in managing the complex and heterogeneous needs of PD patients.
The future of PD treatment lies in disease-modifying therapies that can slow or halt neurodegeneration. With numerous clinical trials targeting α-synuclein aggregation, LRRK2 inhibition, and other pathogenic mechanisms, the prospect of meaningful disease modification is increasingly realistic. Meanwhile, comprehensive care incorporating pharmacological, surgical, lifestyle, and supportive approaches remains essential for optimizing outcomes in patients living with Parkinson's disease.
Dorsey ER, et al. [Global, regional, and national burden of Parkinson's disease](https://doi.org/10.1016/S1474-4422(18). 2018. ↩︎
Kalia LV, Lang AE. [Parkinson's disease](https://doi.org/10.1016/S0140-6736(14). 2015. ↩︎
Chaudhuri KR, et al. Non-motor symptoms of Parkinson's disease. 2011. ↩︎
Cotzias GC, et al. L-dopa for Parkinson's disease. 1968. ↩︎
Jankovic J, Tan EK. Parkinson's disease: etiopathogenesis and treatment. 2020. ↩︎
Fahn S. How do you treat motor complications in Parkinson's disease? J Neurol. 2005. ↩︎
Nutt JG, et al. The pharmacology of levodopa. 2014. ↩︎
Parkinson Study Group. A randomized controlled trial of immediate versus delayed levodopa therapy. N Engl J Med. 1989;321(16):1064-1071. 1989. ↩︎
Stocchi F, et al. COMT inhibitors for Parkinson's disease. 2015. ↩︎
Nyholm D, et al. Duodopa: intestinal gel for Parkinson's disease. 2012. ↩︎
Olanow CW, et al. Continuous subcutaneous levodopa delivery. 2020. ↩︎
Hauser RA, et al. Levodopa/carbidopa/entacapone: a fixed-dose combination treatment. 2006. ↩︎
Poewe W, et al. Diagnosis and management of Parkinson's disease in adults. 2020. ↩︎
Jankovic J. Levodopa strengths and weaknesses. 2002. ↩︎
Ahlskog JE, Muenter MD. Frequency of levodopa-related dyskinesias. 2001. ↩︎
Bonuccelli U, et al. Dopamine agonists in Parkinson's disease. 2002. ↩︎
Schapira AH, et al. Therapeutic advances in Parkinson's disease. 2019. ↩︎
Hubble JP, et al. Pramipexole in Parkinson's disease. 2000. ↩︎
Adler CH, et al. Ropinirole for Parkinson's disease. 2004. ↩︎
Watts RL, et al. Rotigotine transdermal system for Parkinson's disease. 2010. ↩︎
Katzenschlager R, et al. Apomorphine in Parkinson's disease. 2018. ↩︎
Weintraub D, et al. Impulse control disorders in Parkinson's disease. 2010. ↩︎
Riederer P, Laux G. MAO-B inhibitors for Parkinson's disease. 2011. ↩︎
The Parkinson Study Group. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med. 1989;321(20):1364-1371. 1989. ↩︎
Olanow CW, et al. A double-blind, delayed-start trial of rasagiline in Parkinson's disease. 2009. ↩︎
Schapira AH, et al. Safinamide in Parkinson's disease. 2017. ↩︎
Finberg JP, et al. Pharmacology of rasagiline. 2010. ↩︎
Youdim MB, et al. The pharmacology of selegiline. 1993. ↩︎
Antonini A, et al. Continuous dopaminergic stimulation in Parkinson's disease. 2016. ↩︎
Brooks DJ, et al. Enteral levodopa/carbidopa gel infusion for Parkinson's disease. 2014. ↩︎
Ferreira JJ, et al. Opicapone for Parkinson's disease. 2016. ↩︎
Waters CH, et al. Tolcapone in Parkinson's disease. 1997. ↩︎
Muller T, et al. COMT inhibition in Parkinson's disease. 2015. ↩︎
Lees AJ, et al. Tolcapone and hepatotoxicity. 2000. ↩︎
Fahn S, et al. Anticholinergic therapy for Parkinson's disease. 2009. ↩︎
Bravi D, et al. Trihexyphenidyl in Parkinson's disease. 1994. ↩︎
Fahn S, et al. Practice parameter: therapies for Parkinson disease. 2010. ↩︎
Thanvi BR, Lo TC. Anticholinergic drugs in Parkinson's disease. 2005. ↩︎
Joseph C, et al. Anticholinergic use in Parkinson's disease. 2019. ↩︎
Hubsher G, et al. Amantadine: a review of use in movement disorders. 2012. ↩︎
Sawada H, et al. Clinical practice guidelines for amantadine. 2015. ↩︎
Zoldan L, et al. Amantadine in Parkinson's disease. 1995. ↩︎
Ahlskog JE, Muenter MD. Frequency of levodopa-related dyskinesias. 2001. ↩︎
Nutt JG, et al. Management of motor fluctuations in Parkinson's disease. 2002. ↩︎
Poewe W, et al. Continuous dopaminergic stimulation. 2009. ↩︎
Antonini A, et al. Adding dopamine agonists to levodopa. 2007. ↩︎
Stocchi F, et al. Adjunct therapy in Parkinson's disease. 2013. ↩︎
Muller T, et al. COMT inhibition in Parkinson's disease. 2015. ↩︎
Trenkwalder C, et al. Apomorphine infusion in Parkinson's disease. 2020. ↩︎
Jankovic J. Motor fluctuations and dyskinesias in Parkinson's disease. 2006. ↩︎
Nutt JG, et al. Levodopa-induced dyskinesias. 2000. ↩︎
Sawada H, et al. Amantadine for dyskinesias in Parkinson's disease. 2010. ↩︎
Jankovic J. Dopamine agonists in Parkinson's disease. 2006. ↩︎
Volkmann J, et al. Deep brain stimulation for Parkinson's disease. 2010. ↩︎
Krack P, et al. Long-term follow-up of deep brain stimulation. 2003. ↩︎
Chahine LM, et al. Sleep disorders in Parkinson's disease. 2019. ↩︎
Zhang J, et al. Melatonin for REM sleep behavior disorder. 2018. ↩︎
Aurora RN, et al. Practice parameters for REM sleep behavior disorder. 2010. ↩︎
Adler CH, et al. Modafinil for excessive daytime sleepiness in Parkinson's disease. 2003. ↩︎
Menza M, et al. Sleep problems in Parkinson's disease. 2010. ↩︎
Kurtis MM, et al. Insomnia in Parkinson's disease. 2020. ↩︎
Liguori C, et al. Cognitive behavioral therapy for insomnia in Parkinson's disease. 2020. ↩︎
Schrag A. Depression in Parkinson's disease. 2004. ↩︎
Menza M, et al. Venlafaxine for depression in Parkinson's disease. 2006. ↩︎
Findeis P, et al. Nortriptyline in Parkinson's disease depression. 2003. ↩︎
Cummings JL, et al. Pimavanserin for Parkinson's disease psychosis. 2014. ↩︎
Frisina PG, et al. Quetiapine for Parkinson's disease psychosis. 2009. ↩︎
Cheng AV, et al. Clozapine in Parkinson's disease psychosis. 2006. ↩︎
Mamikonyan E, et al. Impulse control disorders in Parkinson's disease. 2008. ↩︎
Vitale C, et al. Behavioral therapies for impulse control disorders. 2011. ↩︎
Roy A, et al. Naltrexone for impulse control disorders. 2011. ↩︎
Freeman R, et al. Consensus statement on the treatment of orthostatic hypotension. 2014. ↩︎
Low PA, et al. Fludrocortisone for orthostatic hypotension. 2011. ↩︎
Jankovic J, et al. Midodrine in orthostatic hypotension. 1993. ↩︎
Sakakibara R, et al. Constipation in Parkinson's disease. 2015. ↩︎
Zangaglia R, et al. Polyethylene glycol for constipation in Parkinson's disease. 2007. ↩︎
Djaldetti R, et al. Gastrointestinal motility in Parkinson's disease. 1996. ↩︎
Sakakibara R, et al. Urinary dysfunction in Parkinson's disease. 2011. ↩︎
Araki I, et al. [Urinary retention in Parkinson's disease](https://doi.org/10.1016/S0022-510X(00). 2000. ↩︎
Aarsland D, et al. Parkinson's disease dementia. 2011. ↩︎
Emre M, et al. Rivastigmine for dementia associated with Parkinson's disease. 2004. ↩︎
Lleo A, et al. Donepezil in Parkinson's disease dementia. 2006. ↩︎
Aarsland D, et al. Memantine in Parkinson's disease dementia. 2009. ↩︎
Krack P, et al. Deep brain stimulation for Parkinson's disease. 2003. ↩︎
Okun MS. Deep brain stimulation for Parkinson's disease. 2012. ↩︎
Bronstein JM, et al. Deep brain stimulation for Parkinson's disease. 2011. ↩︎
Weaver FM, et al. Randomized trial of deep brain stimulation for Parkinson disease. 2009. ↩︎
Ramirez-Zamora A, et al. Deep brain stimulation devices. 2016. ↩︎
Laitinen LV, et al. Pallidotomy for Parkinson's disease. 1992. ↩︎
Jankovic J, et al. Thalamotomy for movement disorders. 1995. ↩︎
Martinez-Fernandez R, et al. Focused ultrasound for Parkinson's disease. 2016. ↩︎
Poewe WH, et al. Apomorphine for acute rescue. 2020. ↩︎
Trenkwalder C, et al. Subcutaneous apomorphine infusion. 2015. ↩︎
Bridi JC, Hirth F. Alpha-synuclein and neurodegeneration. 2018. ↩︎
Schneeberger A, et al. Alpha-synuclein immunotherapy. 2018. ↩︎
Boddapati S, et al. Alpha-synuclein aggregation inhibitors. 2020. ↩︎
Kordower JH, et al. Gene therapy for alpha-synuclein. 2011. ↩︎
Cookson MR. LRRK2 and Parkinson's disease. 2009. ↩︎
Jennings D, et al. LRRK2 inhibition in Parkinson's disease. 2020. ↩︎
Andersen MA, et al. DNL151: a potent LRRK2 inhibitor. 2020. ↩︎
Sidransky E, et al. Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. 2009. ↩︎
Peterschmitt MJ, et al. Venglustat in GBA-PD. 2021. ↩︎
Narayan A, et al. Glucocerebrosidase for Parkinson's disease. 2021. ↩︎
Ahlskog JE. Does vigorous exercise have a neuroprotective effect in Parkinson disease? Neurology. 2011. ↩︎
Schootemeijer S, et al. Physical therapy in Parkinson's disease. 2022. ↩︎
Li F, et al. Tai chi and postural stability in Parkinson's disease. 2012. ↩︎
Shulman LM, et al. Resistance exercise in Parkinson's disease. 2013. ↩︎
Mehrholz J, et al. Treadmill training for Parkinson's disease. 2017. ↩︎
Ramig LO, et al. LSVT LOUD: speech therapy for Parkinson's disease. 2018. ↩︎
Mattson MP. Energy intake and exercise as determinants of brain health. 2020. ↩︎
Seidl SE, et al. Nutrition and Parkinson's disease. 2014. ↩︎
Aiello M, et al. Weight changes in Parkinson's disease. 2015. ↩︎
Ramig LO, et al. LSVT LOUD and LSVT BIG. 2018. ↩︎
Kalf JG, et al. Swallowing problems in Parkinson's disease. 2012. ↩︎
Nijkrake MJ, et al. Occupational therapy in Parkinson's disease. 2007. ↩︎
Barker RA, et al. Stem cell therapy for Parkinson's disease. 2015. ↩︎
Takahashi J. iPSC for Parkinson's disease. 2020. ↩︎
Lindvall O. Clinical translation of stem cell therapy. 2017. ↩︎
LeWitt PA, et al. [AAV2-GAD gene therapy](https://doi.org/10.1016/S1474-4422(11). 2011. ↩︎
Christine CW, et al. AADC gene therapy for Parkinson's disease. 2019. ↩︎
Marks WJ Jr, et al. AAV2-neurturin for Parkinson's disease. 2010. ↩︎
Chahine LM, et al. Biomarkers in Parkinson's disease. 2021. ↩︎
Schapira AH, et al. Personalized medicine in Parkinson's disease. 2017. ↩︎
Seppi K, et al. Update on treatments for non-motor symptoms of Parkinson's disease—an evidence-based medicine review. 2019. ↩︎
Grimes D, et al. Canadian guidelines for Parkinson's disease. 2019. ↩︎
Fernandez HH, et al. Management of advanced Parkinson's disease. 2015. ↩︎